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A single primer pair amplifying a cytochrome P-450 lanosterol-14a-demethylase (L1A1) gene fragment that
encodes a highly conserved region was used to detect yeast DNA in clinical specimens. Positive PCR products
were obtained from genomic DNAs of Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondii, C. krusei,
C. (Torulopsis) glabrata, and C. kefyr. No human, bacterial, or parasitic DNA was amplified. The sensitivity was
evaluated for C. albicans genomic DNA by using various DNA concentrations (200 pg to 2 fg). The amplified
DNAs of Candida species with unknown P-450 L1A1 gene sequences were subcloned and sequenced. Identifi-
cation at the species level was achieved by digestion of the PCR products with different restriction enzymes. A
specific restriction enzyme analysis pattern was determined for each species investigated. Subsequently, we
used PCR to detect specific yeast DNA directly with clinical specimens such as blood and bronchoalveolar
lavage specimens. After appropriate treatment, the specimens were processed by PCR and the results were
compared with those obtained by traditional diagnostic procedures such as cultures and serology. Although
preliminary, the PCR results seem to correlate well, at least for blood, with those of antigen detection assays
and traditional blood cultures, with a better and earlier detection of candidemia.
The hematogenous spread of yeasts occurs frequently in
immunocompromised patients and leads to severe life-threat-
ening disseminated mycoses. Conventional blood cultures are
not very effective in detecting yeast growth and take too long to
become positive (26), although great progress has been made
in recent years (7). Alternative procedures such as the detec-
tion of circulating antigens, enzymes, or metabolic products
(17, 26, 31, 33) lack sensitivity and, to some extent, specificity,
so diagnosis can be delayed or in most cases is obtained only at
autopsy (4, 8, 10, 25, 26). Since candidosis is the most common
disseminated fungal infection in leukemia or cancer patients,
an early diagnosis of candidemia is therefore of great impor-
tance for patient care, especially if it leads to the selection of a
rapid, species-specific antifungal therapy, which could likely
reduce mortality (8).
Amplification of a small amount of yeast-specific DNA in
clinical specimens by PCR technology provides a more rapid
and sensitive approach to the diagnosis of disseminated can-
didosis. Since 1990, several studies have been published on the
detection of fungal DNA in clinical specimens (blood and
bronchoalveolar lavage specimens) by the use of PCR. Detec-
tion of Candida DNA has been obtained by PCR amplification
of ribosomal (9, 25, 29, 32), actin (14), heat shock protein 90
(6), and chitin synthase (12) genes. For filamentous fungi, PCR
amplification of fungal DNA in clinical specimens has been
successfully used for Aspergillus, Penicillium, and Verticillium
spp. (18–20, 22, 30). Most of these studies, especially those on
yeast DNA amplification, were limited by the presence of un-
specific amplified products (2), by the inability to amplify DNA
from Candida species other than Candida albicans, or by the
small number of Candida species whose DNA could be ampli-
fied (3). Specific amplification of DNA from numerous impor-
tant yeasts, including Cryptococcus neoformans and Tricho-
sporon beigelii, resulted from the use of primer sets which
amplify a fragment of the cytochrome P-450 lanosterol-14a
demethylase (L1A1) gene (2, 3). This gene is fungus specific,
and its product catalyzes the conversion of lanosterol to ergos-
terol, which is an essential component of the fungal plasma-
lemma and the main target of most antifungal drugs.
In the present study, a pair of primers, selected from the
constant region of the P-450 L1A1 gene, which codifies for the
active site of the enzyme, amplified a 300- to 350-bp segment
of this gene from the genomic DNAs of numerous isolates
of the Candida species C. albicans, C. tropicalis, C. krusei, C.
(Torulopsis) glabrata, C. guilliermondii, C. parapsilosis, and C.
kefyr. Moreover, restriction enzyme analysis (REA) of the
PCR products allowed us to identify amplified Candida DNA
at the species level. The diagnostic usefulness of these primers
was studied by detecting and identifying Candida DNA in
blood and bronchoalveolar lavage specimens from immuno-
compromised and surgical patients.
MATERIALS AND METHODS
Isolates. Yeasts were isolated from clinical specimens submitted to our labo-
ratory for suspected fungal infections. The most representative species, in order
of frequency of isolation, were C. albicans, C. glabrata, C. krusei, C. tropicalis, C.
parapsilosis, C. kefyr, and C. guilliermondii. They were identified by the germina-
tion tube test in bovine fetal serum, with the yeast biochemical cards of the Vitek
Automicrobic System (BioMerieux, Rome, Italy), and by micromorphology on
rice extract agar. The total numbers of yeast isolates used in the study were 39 C.
albicans, 20 C. glabrata, 20 C. krusei, 15 C. tropicalis, 10 C. parapsilosis, 10 C. kefyr,
and 5 C. guilliermondii isolates. In addition, C. albicans CDC B 385 (Centers for
Disease Control and Prevention [CDC], Atlanta, Ga.), C. tropicalis CBS 94
(Centraalbureau voor Schimmelcultures [CBS], Baarn, The Netherlands), C.
glabrata CBS 138, and C. krusei CBS 573 were tested as type strains.
DNA extraction. Yeast cells were cultured on YEPD broth (1% yeast extract,
2% peptone, 2% dextrose) and were incubated overnight at 378C under shaking
conditions (240 rpm). The yeast cells were collected by centrifugation (1.5 ml of
the broth culture at 10,000 3 g for 5 min), suspended in 1 ml of 1 M sorbitol,
centrifuged again, and resuspended in 1 ml of 1 M sorbitol–50 mM phosphate
buffer (pH 7.5) containing 2% b-mercaptoethanol and 2 mg of yeast lytic enzyme
(ICN, Aurora, Ohio). After 1 h of incubation at 378C and microscopic visual-
ization of the spheroplasts, the cells were centrifuged at 8,000 3 g for 5 min,
suspended in 0.5 ml of 50 mMEDTA (pH 8.0)–0.2% sodium dodecyl sulfate, and
incubated at 708C for 30 min. After the addition of 5 M potassium acetate (50 ml;
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pH 5.4), the suspension was left at 08C for 30 min and then centrifuged at
10,000 3 g for 20 min. The supernatant was treated with RNase (10 mg/ml for 30
min at 378C), and then the DNA was extracted with an equal volume of chlo-
roform-isoamyl alcohol (24/1; three times). This DNA, after purification by
passage through a Sephadex G50 column, was precipitated with cold ethanol at
2708C for 30 min and centrifuged at 10,000 3 g for 20 min. The pellet was then
suspended in 100 ml of TE (10 mM Tris-HCl, 1 mM EDTA [pH 8.0]). Human,
bacterial, and parasitic DNAs were extracted from cutaneous biopsy specimens,
Escherichia coli and Pseudomonas aeruginosa, and Trichomonas vaginalis, respec-
tively by standard procedures (21, 27).
PCR assay. The synthetic oligonucleotides used were primer P4501 (base pairs
1021 to 1043; 59-ATGACTGATCAAGAAATYGCTAA-39), primer P4502 (base
pairs 1370 to 1351; 59-TAACCTGGAGAAACYAAAAC-39), and the internal
probe P450 int (base pairs 1063 to 1082; 59-ATGGGTGGTCAACATACTTC-
39). The base pair numbers refer to the locations within the published P-450
L1A1 gene sequence of C. albicans (16).
DNA (200 pg) was added to 100 ml of the PCR master mixture: 10 ml of a 103
PCR buffer (100 mM Tris-HCl [pH 8.3], 500 mM KCl, 15 mM MgCl2), 16 ml of
a mixture of 200 mM each deoxynucleoside triphosphate (equimolar concentra-
tions of dATP, dCTP, dGTP, and dTTP), 50 ng of each primer, and 2.5 U of Taq
DNA polymerase (Boehringer Mannheim, Mannheim, Germany), with the re-
maining volume made up with sterile distilled water. The PCR was performed in
a thermal cycler (Gene Amp PCR System 9600; Perkin-Elmer). The first cycle
included 3 min of denaturation at 948C, 1 min of annealing at 498C, and 1 min
and 30 s of primer extension at 728C, followed by 40 cycles of 45 s of denaturation
at 948C, 1 min of annealing at 498C, and 1 min and 30 s of extension at 728C.
The PCR products were electrophoresed in an agarose gel (2%) for 1 h and 30
min at 70 V at room temperature in TAE buffer (40 mM Tris acetate, 1 mM
EDTA [pH 8.4]), stained with ethidium bromide, and visualized with UV light
(302 nm). To assess sensitivity, serial dilutions of C. albicans DNA (200 pg to 2
fg) were used in the PCR assay. The amplified electrophoresed fragments were
transferred onto a nylon membrane by standard procedures (21) and were
hybridized with the P450 int 39 digoxigenin-labeled probe according to the
manufacturer’s instructions (DIG oligonucleotide 39 end labeling kit; DIG DNA
detection kit from Boehringer Mannheim).
Cloning and sequencing of the PCR products. The PCR products of C. para-
psilosis, C. kefyr, and C. guilliermondii were cloned in plasmid pUC19 at the SmaI
site and were sequenced in a Sequigen apparatus (Bio-Rad) by using the Seque-
nase, version 2.0, sequencing kit (U.S. Biochemicals) with [a-35S]dATP (Amer-
sham) according to the manufacturer’s instructions.
REA procedure. The PCR products were subjected to REA by using Sau3A,
HincII, and NsiI according to the manufacturer’s instructions. After digestion,
the DNAs were subjected to electrophoresis in an agarose gel (4% gel [3%
SeaKem GTG and 1% Nusieve] in TAE buffer) at 70 V for 2 h at room
temperature and were then stained with ethidium bromide (0.5 mg/ml) and
photographed with UV light.
Preparation of clinical specimens. Bronchoalveolar lavage specimens (1 ml; 20
specimens from 20 leukemia or AIDS patients) were centrifuged at 10,000 3 g
for 5 min. The supernatant was discarded and the pellet (washed two times with
phosphate-buffered saline [PBS]) was resuspended in 1 ml of PBS and stored at
48C until it was used for DNA extraction. Blood samples (3 ml; 21 samples from
18 patients) were collected in tubes containing EDTA and were then diluted
1:1 with sterile PBS (pH 7.2) and added to 3 ml of Ficoll (Diatrizoate-Ficoll;
EUROBIO, Les Ulis, France). The samples were centrifuged at 1,200 3 g for 30
min to collect leukocytes and yeast cells. After two washes in PBS (30 ml), the
cells (leukocytes and yeast cells) were resuspended in 1 ml of PBS and were
stored at 48C until they were used. Extraction of yeast DNA from the processed
clinical specimens was done by the method of Rand et al. (25). Briefly, samples
were centrifuged at 10,000 3 g for 10 min in an Eppendorf microcentrifuge, and
the pellets were resuspended in 0.5 ml of lysing solution (0.5% Nonidet P-40,
0.5% Tween 20, and 0.5% Triton X-100 in double-distilled H2O) and warmed at
378C for 15 min. After centrifugation (10,000 3 g for 30 min), the pellets were
resuspended in 0.5 ml of 1 M sorbitol–50 mM phosphate buffer (pH 7.5) con-
taining 2% b-mercaptoethanol and 2 mg of yeast lytic enzyme (ICN), and the
mixture was incubated for 2 h at 378C. The spheroplasts were then lysed with
proteinase K and sodium dodecyl sulfate (0.5 mg/ml and 0.2%, respectively).
After two extractions with phenol-chloroform-isoamyl alcohol (25:24:1), the
DNA was purified by passage through a Sephadex G50 column and was precip-
itated with cold ethanol. The pellet was suspended in 20 ml of sterile distilled
water, and 10 ml was used to perform the PCR as described above. Blood samples
from six healthy people, including three of the authors, taken two times at a
15-day interval were used as negative controls for processing of blood for PCR.
Conventional diagnostic methods. All 20 bronchoalveolar lavage specimens
were also processed and cultured for fungi by standard procedures (23). Fifteen
blood samples from 13 patients were cultured in aerobic and anaerobic bottles
(Plus/aerobic/S* medium and Plus/anaerobic/F* medium, respectively) for the
BACTEC 9240 automated system (Becton Dickinson, Cockeysville, Md.), and all
positive blood cultures were examined microscopically and plated on Bacto
Candida Growth medium (Difco) and Sabouraud dextrose agar. Assays for the
detection of antigen in 19 serum samples were performed with the Candida Tec
kit (Ramco Laboratories, Houston, Tex.). Cultures and serological assays were
also performed, and the results were compared with those of PCR of blood.
Nucleotide sequence accession numbers. The nucleotide sequence data re-
ported in this paper will appear in the EMBL, GenBank, and DDBJ nucleotide
sequence databases under the accession numbers X97680 CGP450L (C. guillier-
mondii), X97682 CKP450L (C. kefyr), and X97681 CPP450L (C. parapsilosis).
RESULTS
Under the experimental conditions described above, we ob-
tained positive PCR products with DNAs extracted from C.
albicans, C. tropicalis, C. glabrata, C. krusei, C. parapsilosis, C.
kefyr, C. guilliermondii, and C. neoformans (Fig. 1), as well as
Saccharomyces cerevisiae, Candida lusitaniae, Candida rugosa,
Candida lambica, and Blastoschizomyces capitatus. No human,
bacterial, or parasitic DNAs were amplified. The primers used
were unable to amplify DNA extracted from Yarrowia lipo-
lytica, Rhodotorula rubra, Rhodotorula glutinis, Rhodotorula
minuta, Aspergillus fumigatus, Aspergillus flavus, Alternaria al-
ternata, and Cladosporium sp.
The sensitivity of the PCR assay was evaluated with DNA at
various concentrations (from 200 pg to 2 fg) of C. albicans
genomic DNA. Our primer set was able to amplify 200 fg of C.
albicans DNA, and Southern blot analysis with the P450 int
probe confirmed the specificity of the amplicon (Fig. 2).
The sizes of the PCR amplicons obtained from yeast species
DNAs corresponded to the sizes that were expected not only
for the species for which the sequences of the amplified frag-
ments are known but also for C. guilliermondii, C. kefyr, and C.
parapsilosis. The amplified products from these three species
were cloned and sequenced; the sequences of the fragments
(Fig. 3) were compared with the published gene sequences of
C. albicans (16), C. tropicalis (5), C. krusei (3), C. glabrata (3),
and S. cerevisiae (13); this comparison resulted in good per-
centages of homology between all species. The closest homol-
ogies observed were 91.3% between C. albicans and C. guillier-
mondii, 84.8% between C. kefyr and S. cerevisiae, and 69.4%
between C. parapsilosis and C. tropicalis. Knowledge of the
sequences of the PCR amplicons enabled us to perform REA
with appropriate restriction enzymes (Fig. 4 and 5); this anal-
ysis resulted in the identification of all seven Candida species
FIG. 1. PCR amplicons from genomic DNAs of C. albicans (lane 2), C.
tropicalis (lane 3), C. guilliermondii (lane 4), C. parapsilosis (lane 5), C. kefyr (lane
6), C. krusei (lane 7), C. glabrata (lane 8), and C. neoformans (lane 9). Lanes 1
and 10, molecular weight markers (Boehringer Mannheim marker VI and
marker V, respectively).
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investigated by the species-specific REA pattern (Table 1).
Concerning the other three species of Candida whose DNAs
were amplified by our primer set, the products that we ob-
tained were smaller than those mentioned above; moreover,
we tested only one isolate of each species, so further investi-
gations need to be done with large numbers of isolates of these
species.
When PCR was applied to the clinical specimens, we ob-
tained positive results for 15 blood samples and 6 bronchoal-
veolar lavage specimens. Most of the patients were at risk for
fungal infections because of their underlying diseases or con-
ditions (leukemia, organ transplant, or AIDS), and a few were
surgical patients. REA of the amplified fragments enabled us
to identify the DNA at the species level. In Table 2, the results
obtained by PCR-REA of blood are compared with culture
results for blood samples submitted by clinicians and antigen
detection assay results, if they were available. PCR gave more
positive results than blood culture, and a better correlation was
obtained by comparison of positive results by PCR and positive
results by antigen detection assays. With the exception of two
patients in whose blood C. kefyr was detected by PCR-REA
and the patient in whose blood C. guilliermondii was detected
by PCR-REA, all patients whose blood was positive by PCR
and with negative blood cultures or for whom blood cultures
were not done had antigen titers of $1:4; these titers can be
considered an expression of possible disseminated candida in-
fection. Negative blood culture results could be due either to
the use of a nonoptimal system or possibly to the fact that
insufficient numbers of yeast cells were inoculated into the
bottles. All blood samples obtained from healthy people gave
negative PCR results. For bronchoalveolar lavage specimens
the PCR results were compared with culture results, and the
results for all except two of the samples correlated well. For the
first of these samples, the PCR result was positive for C. albi-
cans DNA but the culture gave no growth, but a second bron-
choalveolar lavage specimen from the same patient not pro-
cessed by PCR grew C. albicans 7 days later. For the second
sample, PCR results were negative, but C. albicans was isolated
on culture. For the other four samples, the PCR products
identified the organisms in the samples as C. glabrata, C. kefyr,
C. krusei, and C. tropicalis by REA. The same species were
isolated and identified by standard procedures from the cul-
tures.
FIG. 2. Sensitivity of the PCR assay by agarose gel electrophoresis (A) or
Southern blotting (B). Lanes 1, digoxigenin-labeled Boehringer Mannheim
marker VI; lanes 2 through 7, PCR amplicons obtained from serial dilutions of
C. albicans genomic DNA (from 200 pg to 2 fg).
FIG. 3. Nucleotide and deduced amino acid sequences of the PCR-amplified fragments of the P-450 L1A1 genes from C. guilliermondii UCSC CG001 (A), C. kefyr
UCSC Cke005 (B), and C. parapsilosis UCSC CP010 (C).
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DISCUSSION
The increasing incidence of fungemia due to a broad variety
of yeast species in immunocompromised patients and the poor
sensitivity of conventional blood cultures for detecting yeast
growth have made it necessary to use alternative approaches
for the early detection and identification of the causative yeast
species (8, 10, 26, 31, 33). Several PCR approaches have been
used for this purpose (2, 3, 6, 9, 12, 14, 19, 29, 32), and
according to their sensitivities and specificities, each of them
seems promising.
In our study, we used a single primer pair specifically de-
signed to amplify a DNA fragment of 300 to 350 bp of the
highly conserved region of the P-450 L1A1 gene. Its enzymatic
product catalyzes the conversion of lanosterol to ergosterol, an
important component of the fungal membrane. Moreover,
most of the antifungal drugs, especially the azole derivatives,
act on this biosynthetic pathway.
Our amplicons include the nucleotide sequence which en-
codes the amino acid region defined as distal helix I (residues
292 to 327) of the enzyme (1). This helix, which constitutes part
of the active site, is a highly conserved region, and an amino
acid substitution in this region could result in a loss of enzy-
matic activity, as has been demonstrated by Ishida et al. (11)
for S. cerevisiae. In fact, a change in amino acid residue 310
causes a rotational shift of distal helix I, with the subsequent
interaction of the His-317 residue with the heme iron (11). A
point mutation in this region could be implied in the resistance
to azole derivatives of medically important yeasts, and we are
evaluating the possibility that our PCR assay could be useful
for detecting such point mutations by studying a large number
of C. albicans isolates with different patterns of susceptibility to
the azoles.
The primers were able to amplify DNA from a great variety
of yeast species, but not those from Rhodotorula spp., Y. lipo-
lytica, and filamentous fungi, probably because they are dis-
tantly related to the genus Candida. The PCR product alone
did not, however, give information about the species, and iden-
tification of the causative yeast species is important for thera-
peutic approaches, in view of the possible existence of naturally
resistant species (24).
We therefore studied the possibility of identifying our am-
plicons at the species level. For C. albicans, C. tropicalis, C.
glabrata, and C. krusei, knowledge of the nucleotide gene se-
quence that is amplified (3, 5, 16) allowed us to use restriction
enzymes that are useful for obtaining species-specific REA
patterns. For the other clinically relevant Candida species am-
plified, C. kefyr, C. parapsilosis, and C. guilliermondii (15, 28),
the corresponding P-450 L1A1 gene fragments were cloned
and sequenced to define a panel of restriction enzymes which
allowed for the identification of the organisms to the species
level. The close homologies encountered among the seven
major Candida species studied allowed us to use the same
panel of enzymes.
Our PCR approach demonstrated good sensitivity (200 fg of
yeast DNA detected) and, with an additional step (REA pro-
cedure), allowed us to identify all seven species. It could there-
fore be considered useful for detecting and identifying can-
didal DNA direct from clinical specimens.
We therefore tested it with blood and obtained interesting
results. Although the results are only preliminary, they indicate
that PCR is more sensitive than blood culture for detecting
yeast, especially in febrile patients unresponsive to antibiotic
treatment, as were most of the patients whose blood was in-
vestigated. In this case, clinicians, especially hematologists,
begin empiric antifungal treatment with amphotericin B. We
were able to detect C. albicans DNA from a patient whose
blood was culture positive for P. aeruginosa, which could have
masked the detection of the yeast by culture. In addition, a few
patients treated with antimycotic drugs on the basis of the
positive PCR results showed marked clinical improvement,
and for one patient (patient 14) a complete cure was achieved.
These results are very preliminary and should be confirmed
FIG. 4. Patterns of amplified products of three Candida spp. digested with
HincII (lanes H), NsiI (lanes N), and Sau3A (lanes S). Lane MVI, Boehringer
Mannheim marker VI; lane MV, Boehringer Mannheim marker V.
FIG. 5. Patterns of amplified products of four Candida spp. digested with
HincII (lanes H), NsiI (lanes N), and Sau3A (lanes S). Lanes MVI, Boehringer
Mannheim marker VI; lanes MV, Boehringer Mannheim marker V.
TABLE 1. REA patterns obtained from the seven Candida species
amplicons according to the different lengths of the fragments
Species
Fragment size (bp)
Uncut
amplicon HincII NsiI Sau3A
C. albicans 350 300, 50 243, 107 343
C. glabrata 343 290, 53 343 213, 130
C. guilliermondii 336 283, 53 240, 96 277, 52
C. kefyr 338 288, 50 338 306
C. krusei 350 155, 139, 56 350 343
C. parapsilosis 350 214, 136 350 343
C. tropicalis 350 161, 138, 51 350 231, 114
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with a larger number of patients. The occurrence of the yeast
species detected in blood by PCR reflects our epidemiological
data for blood cultures positive for yeasts; except for C. kefyr,
this finding is unusual and could be considered a transient
candidemia due to the inoculation of the yeast into the blood-
stream from the skin (the patients were receiving parenteral
nutrition) or during the operation (all the three C. kefyr-posi-
tive subjects were surgical patients). Colonization with yeasts
(Table 2) does not seem to have an effect on the PCR results,
as demonstrated for PCR-negative patients 10, 11, 15, and 16
with mucocutaneous candidosis or some PCR-positive patients
(patients 2, 4, 5, 6, and 7) who were not colonized. For bron-
choalveolar lavage specimens, the PCR results were compara-
ble to those obtained by traditional cultures, being discordant
only for two patients: one patient was PCR positive and culture
negative, and one patient was PCR negative and culture pos-
itive.
The processing of blood specimens by the addition of Ficoll
improves the detection of fungal DNA, since it eliminates
erythrocytes, which could have an inhibitory effect on PCR
assays, and separates yeast cells, as demonstrated with seeded
specimens, in the same fraction of leukocytes.
However, the occurrence of false-positive or false-negative
PCR results must be investigated with a larger number of
specimens from patients at risk of developing disseminated
fungal infections. To validate our PCR-REA system, we are
performing a study with a larger number of patients with he-
matological malignancies who have fever of unknown origin
and who are still febrile after 3 days of treatment with broad-
spectrum antibiotics. These patients will be enrolled in the
study before they receive empiric antifungal therapy and will
be followed during the course of antifungal treatment by PCR
of blood samples, and cultures of blood with Plus/fungal me-
dium bottles from Becton Dickinson will be performed simul-
taneously. There is also the need to differentiate transient from
sustained candidemias and to apply our PCR assay to the
detection of C. neoformans in cerebrospinal fluid and blood
specimens from patients under antimycotic treatment with per-
sistent titers of antigen in cerebrospinal fluid and blood and
negative cultures.
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